CL2014000450A1 - Compuestos derivados de n-(heteroarilmetil)-6-[(2-heteroarilciclopropil)metoxi]pririmidin-4-amina, inhibidores de pde10; composicion farmaceutica; y su uso para el tratamiento de un trastorno seleccionado de trastornos psicóticos, delirantes, entre otros. - Google Patents
Compuestos derivados de n-(heteroarilmetil)-6-[(2-heteroarilciclopropil)metoxi]pririmidin-4-amina, inhibidores de pde10; composicion farmaceutica; y su uso para el tratamiento de un trastorno seleccionado de trastornos psicóticos, delirantes, entre otros.Info
- Publication number
- CL2014000450A1 CL2014000450A1 CL2014000450A CL2014000450A CL2014000450A1 CL 2014000450 A1 CL2014000450 A1 CL 2014000450A1 CL 2014000450 A CL2014000450 A CL 2014000450A CL 2014000450 A CL2014000450 A CL 2014000450A CL 2014000450 A1 CL2014000450 A1 CL 2014000450A1
- Authority
- CL
- Chile
- Prior art keywords
- pririmidin
- heteroarylcyclopropyl
- heteroarylmethyl
- delusions
- methoxy
- Prior art date
Links
- 206010012239 Delusion Diseases 0.000 title 1
- 208000028017 Psychotic disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 231100000868 delusion Toxicity 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161527392P | 2011-08-25 | 2011-08-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014000450A1 true CL2014000450A1 (es) | 2014-08-22 |
Family
ID=47746797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014000450A CL2014000450A1 (es) | 2011-08-25 | 2014-02-25 | Compuestos derivados de n-(heteroarilmetil)-6-[(2-heteroarilciclopropil)metoxi]pririmidin-4-amina, inhibidores de pde10; composicion farmaceutica; y su uso para el tratamiento de un trastorno seleccionado de trastornos psicóticos, delirantes, entre otros. |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US9062059B2 (es) |
| EP (1) | EP2748151B1 (es) |
| JP (1) | JP5648147B2 (es) |
| KR (1) | KR101655635B1 (es) |
| CN (1) | CN103917528B (es) |
| AR (1) | AR087628A1 (es) |
| AU (1) | AU2012299080B2 (es) |
| BR (1) | BR112014004310B8 (es) |
| CA (1) | CA2845578C (es) |
| CL (1) | CL2014000450A1 (es) |
| CO (1) | CO6890101A2 (es) |
| CR (1) | CR20140085A (es) |
| CY (1) | CY1117622T1 (es) |
| DK (1) | DK2748151T3 (es) |
| DO (1) | DOP2014000039A (es) |
| EA (1) | EA023685B1 (es) |
| ES (1) | ES2572527T3 (es) |
| HR (1) | HRP20160635T1 (es) |
| HU (1) | HUE028451T2 (es) |
| IL (1) | IL230997A (es) |
| MA (1) | MA35508B1 (es) |
| ME (1) | ME02419B (es) |
| MX (1) | MX357241B (es) |
| MY (1) | MY157301A (es) |
| NI (1) | NI201400014A (es) |
| PE (1) | PE20141535A1 (es) |
| PH (1) | PH12014500424A1 (es) |
| PL (1) | PL2748151T3 (es) |
| RS (1) | RS54788B1 (es) |
| SG (1) | SG2014013536A (es) |
| SI (1) | SI2748151T1 (es) |
| TN (1) | TN2014000070A1 (es) |
| TW (1) | TWI450895B (es) |
| UA (1) | UA109735C2 (es) |
| WO (1) | WO2013028590A1 (es) |
| ZA (1) | ZA201401272B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2763672B1 (en) | 2011-10-06 | 2016-08-10 | Merck Sharp & Dohme Corp. | 1,3-substituted azetidine pde10 inhibitors |
| EP2763533B1 (en) | 2011-10-06 | 2021-12-29 | Merck Sharp & Dohme Corp. | Triazolyl pde10 inhibitors |
| US9359348B2 (en) | 2012-11-15 | 2016-06-07 | Merck Sharp & Dohme Corp. | Cyclopropyl imidazopyridine PDE10 inhibitors |
| TW201422610A (zh) | 2012-11-15 | 2014-06-16 | Merck Sharp & Dohme | 作爲ｐｄｅ１０抑制劑之經二級醇取代之三唑 |
| EP2919781B1 (en) | 2012-11-15 | 2017-06-28 | Merck Sharp & Dohme Corp. | Cyclobutyl benzimidazoles as pde10 inhibitors |
| EP2922543B1 (en) | 2012-11-20 | 2017-05-24 | Merck Sharp & Dohme Corp. | Substituted pyridone derivatives as pde10 inhibitors |
| US9663513B2 (en) | 2012-11-20 | 2017-05-30 | Merck Sharp & Dohme Corp. | Pyrimidine PDE10 inhibitors |
| WO2014139150A1 (en) * | 2013-03-15 | 2014-09-18 | Merck Sharp & Dohme Corp. | Substituted pyridizinone derivatives as pde10 inhibitors |
| KR101733441B1 (ko) | 2014-03-24 | 2017-05-10 | 노파르티스 아게 | 박테리아 감염의 치료를 위한 모노박탐 유기 화합물 |
| EP3544958B1 (en) | 2016-11-28 | 2021-03-24 | Boehringer Ingelheim International GmbH | Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| CN112262132A (zh) | 2018-06-27 | 2021-01-22 | 豪夫迈·罗氏有限公司 | 作为大麻素受体2的抑制剂的新型吡啶和吡嗪化合物 |
| CN112119068A (zh) | 2018-06-27 | 2020-12-22 | 豪夫迈·罗氏有限公司 | 作为大麻素受体2的抑制剂的新型氮杂环丁烷-取代的吡啶和吡嗪化合物 |
| CN112638430B (zh) | 2018-06-27 | 2023-05-16 | 豪夫迈·罗氏有限公司 | 放射性标记的大麻素受体2配体 |
| KR102892626B1 (ko) * | 2020-06-05 | 2025-11-28 | 노에마 파르마 아게 | 투렛 증후군의 치료를 위한 포스포디에스테라제 10 억제제의 용도 |
| MX2023010824A (es) | 2021-03-17 | 2023-09-28 | Merck Sharp & Dohme Llc | Profarmacos de compuestos de pde10. |
| WO2023184486A1 (en) * | 2022-04-01 | 2023-10-05 | Merck Sharp & Dohme Llc | Process for preparing ( (1s, 2s) -2- (5-methylpyridin-2-yl) cyclopropyl) -methanol |
| CN115403527B (zh) * | 2022-07-20 | 2024-03-29 | 西安近代化学研究所 | 一种还原胺化法合成杀菌剂乙嘧酚的方法 |
| WO2024049721A1 (en) * | 2022-08-31 | 2024-03-07 | Merck Sharp & Dohme Llc | Sustained release delivery of a pde10 inhibitor |
| WO2024099135A1 (zh) * | 2022-11-11 | 2024-05-16 | 杭州中美华东制药有限公司 | 1,5-萘啶类cGAS抑制剂及其用途 |
| CR20250405A (es) * | 2023-03-29 | 2025-10-10 | Merck Sharp & Dohme Llc | Formulaciones de pde10a de liberación controlada |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA06014236A (es) | 2004-06-07 | 2007-02-14 | Pfizer Prod Inc | Inhibicion de la fosfodiesterasa 10 como tratamiento para las afecciones relacionadas con el sindrome metabolico y con la obesidad. |
| CA2583654C (en) | 2004-10-12 | 2015-02-17 | Maxlinear, Inc. | A receiver architecture with digitally generated intermediate frequency |
| CN102491969B (zh) | 2005-01-07 | 2015-08-19 | 辉瑞产品公司 | 杂芳族喹啉化合物及其作为pde10抑制剂的用途 |
| GB0506883D0 (en) | 2005-04-05 | 2005-05-11 | Astrazeneca Ab | Chemical compounds |
| JP2008534662A (ja) * | 2005-04-05 | 2008-08-28 | アストラゼネカ アクチボラグ | 抗癌剤として使用されるピリミジン誘導体 |
| NL2000397C2 (nl) * | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclische heteroarylverbindingen als PDE10 inhibitoren. |
| US20090176829A1 (en) | 2006-05-02 | 2009-07-09 | Pfizer Inc | Bicyclic heteroaryl compounds as pde10 inhibitors |
| EP2327704A4 (en) * | 2008-08-29 | 2012-05-09 | Shionogi & Co | RING-CONDENSED AZOL DERIVATIVE WITH PI3K-INHIBITING EFFECT |
| US20110160206A1 (en) | 2008-09-04 | 2011-06-30 | Eiji Kawanishi | Tri-substituted pyrimidine compounds and their use as pde10 inhibitors |
| US20110166135A1 (en) | 2008-09-10 | 2011-07-07 | Hiroshi Morimoto | Aromatic nitrogen-containing 6-membered ring compounds and their use |
| AR074343A1 (es) * | 2008-11-14 | 2011-01-12 | Amgen Inc | Derivados de piridina y pirimidina como inhibidores de la fosfodiesterasa 10 |
| ES2397934T3 (es) * | 2008-12-17 | 2013-03-12 | Amgen Inc. | Compuestos de aminopiridina y carboxipiridina como inhibidores de fosfodiesterasa 10 |
| WO2011008931A2 (en) * | 2009-07-15 | 2011-01-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders |
| TWI481607B (zh) * | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物 |
| US8470820B2 (en) | 2010-01-22 | 2013-06-25 | Hoffman-La Roche Inc. | Nitrogen-containing heteroaryl derivatives |
| US8957077B2 (en) * | 2010-09-30 | 2015-02-17 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine PDE 10 inhibitors |
| US8785467B2 (en) * | 2010-09-30 | 2014-07-22 | Merck Sharp & Dohme Corp. | Alkoxy pyrimidine PDE10 inhibitors |
-
2012
- 2012-08-20 CA CA2845578A patent/CA2845578C/en active Active
- 2012-08-20 KR KR1020147007427A patent/KR101655635B1/ko active Active
- 2012-08-20 EA EA201490492A patent/EA023685B1/ru not_active IP Right Cessation
- 2012-08-20 ES ES12826375.3T patent/ES2572527T3/es active Active
- 2012-08-20 CN CN201280052330.4A patent/CN103917528B/zh active Active
- 2012-08-20 PH PH1/2014/500424A patent/PH12014500424A1/en unknown
- 2012-08-20 UA UAA201403008A patent/UA109735C2/ru unknown
- 2012-08-20 WO PCT/US2012/051522 patent/WO2013028590A1/en not_active Ceased
- 2012-08-20 US US14/239,603 patent/US9062059B2/en active Active
- 2012-08-20 EP EP12826375.3A patent/EP2748151B1/en active Active
- 2012-08-20 RS RS20160357A patent/RS54788B1/sr unknown
- 2012-08-20 MX MX2014002178A patent/MX357241B/es active IP Right Grant
- 2012-08-20 SG SG2014013536A patent/SG2014013536A/en unknown
- 2012-08-20 HU HUE12826375A patent/HUE028451T2/en unknown
- 2012-08-20 MY MYPI2014000504A patent/MY157301A/en unknown
- 2012-08-20 JP JP2014527214A patent/JP5648147B2/ja active Active
- 2012-08-20 PL PL12826375.3T patent/PL2748151T3/pl unknown
- 2012-08-20 BR BR112014004310A patent/BR112014004310B8/pt active IP Right Grant
- 2012-08-20 DK DK12826375.3T patent/DK2748151T3/en active
- 2012-08-20 HR HRP20160635TT patent/HRP20160635T1/hr unknown
- 2012-08-20 AU AU2012299080A patent/AU2012299080B2/en active Active
- 2012-08-20 SI SI201230539A patent/SI2748151T1/sl unknown
- 2012-08-20 PE PE2014000255A patent/PE20141535A1/es active IP Right Grant
- 2012-08-20 TW TW101130166A patent/TWI450895B/zh active
- 2012-08-20 ME MEP-2016-101A patent/ME02419B/me unknown
- 2012-08-22 AR ARP120103086A patent/AR087628A1/es active IP Right Grant
-
2014
- 2014-02-16 IL IL230997A patent/IL230997A/en active IP Right Grant
- 2014-02-18 TN TNP2014000070A patent/TN2014000070A1/en unknown
- 2014-02-19 ZA ZA2014/01272A patent/ZA201401272B/en unknown
- 2014-02-24 NI NI201400014A patent/NI201400014A/es unknown
- 2014-02-24 CR CR20140085A patent/CR20140085A/es unknown
- 2014-02-25 DO DO2014000039A patent/DOP2014000039A/es unknown
- 2014-02-25 CL CL2014000450A patent/CL2014000450A1/es unknown
- 2014-02-27 CO CO14042266A patent/CO6890101A2/es unknown
- 2014-03-13 MA MA6829A patent/MA35508B1/fr unknown
-
2016
- 2016-06-10 CY CY20161100512T patent/CY1117622T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014000450A1 (es) | Compuestos derivados de n-(heteroarilmetil)-6-[(2-heteroarilciclopropil)metoxi]pririmidin-4-amina, inhibidores de pde10; composicion farmaceutica; y su uso para el tratamiento de un trastorno seleccionado de trastornos psicóticos, delirantes, entre otros. | |
| WO2012122383A3 (en) | Pi3 kinase inhibitors and uses thereof | |
| CL2014002873A1 (es) | Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
| CL2015001279A1 (es) | Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras. | |
| HUE060743T2 (hu) | Gyógyszerészeti kompozíciók, amelyek tartalmaznak imidazothiadiazol- és imidazopiridazinszármazékokat mint proteáz aktívált receptor 4 (PAR4) inhibitorokat trombocitaaggregációk kezelésére | |
| BR112014010206A2 (pt) | composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença | |
| EA201591420A1 (ru) | Гетероарильные соединения и их применение | |
| CL2013003051A1 (es) | Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio | |
| DK3074396T3 (da) | 1-(5-tert-butyl-2-arylpyrazol-3-yl)-3-[2-fluor-4-[(3-oxo-4h-pyrido[2,3-b]pyrazin-8-yl)oxy]phenyl]urinstofderivater som raf-inhibitorer til behandling af cancer | |
| BR112014010179A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição | |
| EP2846784A4 (en) | COMPOUNDS FOR PROMOTING PROTEIN REMOVAL AND PROCESS THEREFOR | |
| CL2014000543A1 (es) | Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer. | |
| CL2012003722A1 (es) | Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida. | |
| WO2012158843A3 (en) | Kinase inhibitors | |
| LT3111926T (lt) | Kompozicijos, būdai ir sistemos dviejų arba kelių veikliųjų agentų respiraciniam pateikimui | |
| DK2516433T3 (da) | Substituerede n-(1h-indazol-4-yl)imidazo[1,2-a]pyridin-3-carboxamidforbindelser som cfms-inhibitorer | |
| BR112014010177A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença | |
| CL2014001103A1 (es) | Compuestos derivados de heteroaril piridona y aza-piridona sustituidas, inhibidores de btk quinasa; composicion farmaceutica que los comprende; proceso de preparacion de la composicion farmaceutica; kit farmaceutico; y uso para el tratamiento de trastornos inmunes, cancer, inflamacion, trastornos neurologicos, entre otros. | |
| DK2875005T3 (da) | N-(3-heteroarylaryl)-4-arylarylcarboxamider og analoger som hedgehog pathway inhibitorer, og anvendelse deraf | |
| WO2012100224A3 (en) | Preparation of metal-triazolate frameworks | |
| BR112012022879A2 (pt) | composto, composição farmacêutica, uso do composto e método de tratamento | |
| HRP20170928T1 (hr) | Inhibitori kinurenin-3-monooksigenaze, farmaceutski pripravci, i postupci za njihovu upotrebu | |
| CL2013001591A1 (es) | Compuestos derivados de triazolopiridina; inhibidores de pde10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, entre otras enfermedades. | |
| BRPI0818459A2 (pt) | Composição farmacêutica adequada para uso oftálmico. | |
| DK2773633T3 (da) | Heterocykliske forbindelser, medikamenter indeholdende forbindelserne, anvendelse deraf og fremgangsmåder til fremstilling deraf. |